Clinical Trials

At the Regional Cancer Center we believe that patients and physicians benefit from being involved in clinical trials. Clinical trials help advance the science of cancer care, including new approaches to diagnosis, treatment and support of cancer patients.

The Regional Cancer Center is a member of the Southeast Clinical Oncology Research Consortium (SCOR), bringing more than 150 National cancer Institute sponsored trials to our local community. In addition we partner with other organizations to participate in rese arch in specific areas.

Meet Our Research Team

Our team of cancer experts strives to make the cutting edge technology available across the world acessible right here in Southwest Flroida.

Research Staff

  • Alina Ward, RN, CCRP – Research Nurse
  • Shirley Morrison – Research Coordinator

Breast Surgery

  • David T. Rock, MD, FACS
  • Samith Sandadi, MD, Msc, FACOG

GYN Oncology

  • Edward C. Grendys, Jr., MD
  • James Orr, MD, FACOG, FACS
  • Samith Sandadi, MD, Msc, FACOG

Medical Oncology:

  • Bianca Ferrari, MD (LPG)
  • Venkata Parsa, MD (LPG)
  • Luiz Pita de Oliviera, MD (LPG)

Radiation Oncology

  • Constantine A. Mantz, MD
  • Keith L. Miller, MD
  • Kristina Mirabeau-Beale, MD, MPH

Surgical Oncology

  • Basan Allan, MD
  • Mark Bloomston, MD, FACS

Industry Open Studies

ATHENA/Clovis Oncology ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating
Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
PaTK02/Advantagene, Inc. Neoadjuvant GMCITM Plus Chemoradiation For Advanced Non-metastatic Pancreatic Adenocarcinoma
FL pancreas Collaborative/ Moffit The Florida Pancreas Collaborative Next-Generation Biobank: Reducing Health Disparities and Improving Survival for Pancreatic
Keynote-937/Merck 3475-937 A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as
Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection
or Local Ablation (KEYNOTE-937)
CALLA/Astra Zeneca
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in

Combination With and following Chemoradiotherapy Compared to Chemradiotherapy alone for treatment in Women with locally

advanced Cervical Cancer (CALLA)

SCOR Open Studies

Study ID Study Title Study ID Study Title
BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide
BR003 Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk
Node-Negative Triple-Negative Invasive Breast Cancer
GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III
Study of mFOLFOX6/Bevacizumab Combination Chemotherapy GI004 with or without Atezolizumab
or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch
Repair (dMMR) Metastatic Colorectal Cancer
BR002 A Phase IIR/111 Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT)
and/or BROO2 GY006 Surgical Ablation for Newly Oligometastatic Breast Cancer
GY006 A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous
triapine in women with newly diagnosed bulky stage 1B2, or stage II, IIIB, or IVA cancer of the uterine
cervix or stage II-1VA vaginal cancer.
GU006 A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced
Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer
CC004 Phase II Double Blind Dose Finding Trial of Bupropion CC004 Versus Placebo for Sexual Desire in Women
with Breast or Gynecologic Cancer
A021502 Randomized Trial of Standard Chemotherapy Aloneor Combined with Atezolizumab as Adjuvant Therapy for A021502 51613 Patients
with Stage III Colon Cancer and Deficient DNA Mismatch Repair
S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan
(CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification